Bengt Jöndell continues as acting CFO
2017年5月23日 - 8:34PM
Due to publicity last week about Bengt Jöndell
becoming CFO for another life science company Enzymatica announces
that Bengt will remain as acting CFO on half time for Enzymatica
until a new CFO has been recruited.
For more information, please
contact:
Fredrik Lindberg, CEO Enzymatica AB
Tel: +46 708-86 53 70 | E-post: fredrik.lindberg@enzymatica.com
Enzymatica
Enzymatica is a life science company who develops and sells medical
device products against infectious-related diseases. Over a short
period the company has developed a unique oral spray for colds,
ColdZyme®, and launched it on eight markets. The product has become
one of the leading articles for colds in Swedish pharmacies.
Enzymatica's strategy is to continue growing by strengthening its
position in existing markets and to expand to more geographical
markets through well-established partners. The company is
headquartered in Lund, Sweden and is listed on Nasdaq First North.
For more information, please visit www.enzymatica.com.
Enzymaticas Certified Adviser is Erik Penser
Bank.
Press Release (PDF)
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Enzymatica AB via Globenewswire
ENZYMOTEC LTD. (NASDAQ:ENZY)
過去 株価チャート
から 6 2024 まで 7 2024
ENZYMOTEC LTD. (NASDAQ:ENZY)
過去 株価チャート
から 7 2023 まで 7 2024
Real-Time news about Enzymotec Ltd. - Ordinary Shares (delisted) (ナスダック市場): 0 recent articles
その他のEnzymatica ABニュース記事